Vaccines
We developed the CO-CoVac-01 vaccine candidate against COVID-19 by using an innovative nanoparticle-based platform. CO-CoVac-01 mimics SARS-CoV-2 particles to deliver safe and robust protection.
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| CO-CoVac-01 | SARS CoV-2 | development |
A novel coronavirus SARS-CoV-2, which causes severe respiratory disease COVID-19 is a global threat. By the end of 2020 coronavirus caused 1.500.000 deaths . A potent vaccine that guarantees long-lasting immunity is desperately needed.
We use advanced biochemical engineering to produce nanoparticle vaccine CO-CoVac-01 against COVID-19. The components of the vaccine ensure ultimate protection and safety profile, resulting in prolonged immunity against a broad range of coronavirus infections. CO-CoVac-01 is a next-generation vaccine that expands the protection repertoire beyond the SARS-CoV-2 Spike protein, which is used in first-generation technologies.
Together with other partners we established spin-off Sferogen.
Contact: biotech@cobik.si
